GSK and VIR: Two rising healthcare stocks to explore

December 07, 2021 09:07 AM PST | By Rupam Roy

Google News:

GSK and VIR: Two rising healthcare stocks to explore — Image source: lenetstan,Shutterstock

Recent News

Kalkine : Nasdaq Composite Moves Amid Affirm Options Surge

Kalkine: Stock Market Reacts Mildly After House Passes Trump Tax Bill...

Kalkine:Indexdjx Dji Rises on Trade Talks and Confidence Boost

Kalkine: Intel Drops Amid Rivals’ Launches Dow Jones Industrial Averag...

Highlights

An early-stage study showed that GSK and VIR's Covid-19 treatment is effective against the Omicron variant.

Sotrovimab showed effective results against all 37 mutations in the spike protein of Omicron.

The GSK stock surged over 10% YTD.

GlaxoSmithKline PLC (NYSE:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) stocks were trending on Wall Street Tuesday after their covid drug was found effective against Omicron.

An early-stage study showed the covid drug Sotrovimab was effective against all 37 mutations in the spike protein of Omicron, the Brentford, UK-based GlaxoSmithKline said in a statement. Earlier pre-clinical data also had shown positive results against key Omicron mutations.

Also Read: 10 US-listed Chinese stocks to explore in 2022

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) stocks were trending after their Covid-19 treatment showed positive results against the virus

Also Read: Why are these EV stocks worth watching in 2022?

GlaxoSmithKline PLC (GSK)

GSK stocks were up 0.67% to US$42.0399 at 8:41 am ET on December 7. Its stock value surged 10.65% YTD. The firm has a market cap of US$105.06 billion and an EPS of US$2.36.

The 52-week highest and lowest stock prices were US$43.61 and US$33.53, respectively. Its trading volume was 3,095,473. The company's net sales surged 10% YoY to £9.07 billion in Q3, FY21. It reported adjusted earnings of 36.6p (UK pence) per share.

Also Read: Why did Del Taco (TACO) stock skyrocket 65% today?

Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology is an immunology firm that specializes in infectious diseases.

VIR stocks were priced at US$39.40 at 9:16 am ET on December 7, up 2.63% from their previous closing price. Its market cap is US$5.02 billion, and its EPS is US$-0.87.

The stock's 52-week highest and lowest prices were US$141.01 and US$25.31, respectively. Its trading volume on December 7 was 1,700,895. The firm reported total revenue of US$103.6 million in Q3, FY21, compared to US$1.9 million in the year-ago quarter.

Also Read: Chicago Atlantic IPO: How to buy the stock?

Bottomline

The S&P 500 healthcare sector surged 15.20% YTD while increasing 2.78% QTD. The pre-clinical data from the study of Sotrovimab demonstrate the drug’s potential against the Omicron variant. Healthcare companies, mainly those engaged in covid drug production, have been the top beneficiaries of the growth witnessed in the sector this year.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.